New jab could 'cure' aggressive breast cancer after positive results
Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...
Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression ...
PharmiWeb2d
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC 2024 on November 9, 2024 (see ...
Pharmabiz4d
Transgene & NEC to present new data confirming clinical proof of principle for neoantigen cancer vaccine, TG4050, in head & neck cancer at SITC 2024
Dr. Emmanuelle Dochy, chief medical officer of Transgene, added: "We are very encouraged to observe that all the patients treated with our neoantigen cancer vaccine TG4050 remain disease-free after a ...
FierceBiotech4d
In 'surprise' termination, Genentech drops Nykode partnership for individualized cancer vaccine
Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...
BioSpace5d
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe
Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...